Publications and Presentations

Check out our publications and poster presentations.

December 2018

Efficacy and Safety of CB-839, a Small Molecule Inhibitor of Glutaminase, in Combination With Paclitaxel in Patients With Advanced Triple Negative Breast Cancer (TNBC): Initial Findings from a Multicenter, Open-Label Phase 2 Study

San Antonio Breast Cancer Symposium

June 2018

Phase 1 clinical trial of the glutaminase inhibitor CB-839 plus capecitabine in patients with advanced solid tumors

American Society of Clinical Oncology

June 2018

CANTATA: A randomized phase 2 study of CB-839 in combination with cabozantinib vs. placebo with cabozantinib in patients with advanced/metastatic renal cell carcinoma

American Society of Clinical Oncology

April 2018

The Glutaminase Inhibitor CB-839 Synergizes with CDK4/6 and PARP Inhibitors in Pre-Clinical Tumor Models

American Association of Cancer Research – 2018

February 2018

Phase I study of glutaminase inhibitor CB-839, combined with everolimus or cabozantinib in patients with clear cell and papillary renal cell carcinoma

American Society of Clinical Oncology Genitourinary Cancer Symposium

Our Pipeline

We are focused on solid tumors for
which new treatments are urgently needed.

View Our Pipeline